Fig. 1

Cost differences between responders and nonresponders during 1 year follow-up (n = 2337 per cohort). All-cause medical costs include all costs related to inpatient and outpatient visits, such as office visits and laboratory testing. All-cause pharmacy costs include all costs related to outpatient pharmacy fills, with the exception of fills for biologic drugs (defined as abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, rituximab, tocilizumab, and tofacitinib citrate). Rheumatoid arthritis (RA)-related medical costs include all costs related to inpatient and outpatient visits, such as office visits and laboratory testing, with International Classification of Diseases, Ninth Revision, Clinical Modification, codes for RA noted on the claims. RA-related pharmacy costs include all costs related to outpatient pharmacy fills for conventional synthetic disease-modifying antirheumatic drugs and biologics